McArdle disease with rhabdomyolysis induced by rosuvastatin: Case report

Arquivos de Neuro-Psiquiatria

Volumn 65, Issue 3 B, 2007, Pages 834-837

  Lorenzoni, Paulo José ^a   Silvado, Carlos Eduardo ^a   Scola, Rosana Herminia ^a   Luvizotto, Mario ^a   Werneck, Lineu César ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

McArdle disease; Rhabdomyolysis; Rosuvastatin; Statin myopathy; Toxic myopathy

Indexed keywords

GLYCOGEN; GLYCOGEN PHOSPHORYLASE; OXCARBAZEPINE; ROSUVASTATIN;

ADULT; ARTICLE; CASE REPORT; COMA; CREATINE KINASE BLOOD LEVEL; DRUG WITHDRAWAL; EXERCISE; GLYCOGEN STORAGE DISEASE TYPE 5; HUMAN; HYPERLIPIDEMIA; MALE; MUSCLE CRAMP; MUSCLE FATIGUE; PHYSICAL ACTIVITY; RHABDOMYOLYSIS; SEIZURE; SIDE EFFECT;

EID: 35448994680     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2007000500020     Document Type: Article

References (15)

1. . McArdle B. Myophaty due to a defect in muscle glycogen breakdown. Clin Sci 1951;10:13.
2. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factor associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006;34:153-162.
3. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004;116:408-416.
4. Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006;119:400-409.
5. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004; 4:117-138.
6. Alsheikh-Ali AA, Ambrose MS, Kuvin JK, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005;111:3051-3057.
7. McAfee AT, Ming EE, Seeger JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepid Drug Saf 2006;15:444-453.
8. Werneck LC. The value of muscle biopsy in neurology: a study of 290 biopsies. Rev Bras Clin Ter 1981;10(Suppl):S2-S24.
9. Peres-Calvo J, Civeira-Murillo F, Cabello A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. Q J Med 2005;98:461-464.
10. Tsivgoulis G, Spengos K, Karandreas N, et al. Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med 2006;166:1519-1524.
11. Magalhães MEC. Mechanisms of rhabdomyolysis with statins. Arq Bras Cardiol 2005;85:42-44.
12. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25:649-663.
13. Pfeiffer-Guglielmi B, Fleckenstein B, Jung G, Hamprecht B. Immunocytochemical localization of glycogen phosphorylase isozymes in rat nervous tissues by using isozyme-specific antibodies. J Neurochem 2003;85:73-81.
14. Psarra AMG, Pfeiffer B , Giannakopoulou M, et al. Immunocytochemical localization of glycogen phosphorylase kinase in rat brain sections and in glial and neuronal primary cultures. J Neurocytol 1998;27:779-790.
15. Walker AR, Tschetter K, Matsuo F, Flanigan KM. McArdle's disease presenting as recurrent cryptogenic renal failure due to occult seizures. Muscle Nerve 2003;28:640-643.